Skip to Main Content

National Coverage Analysis (NCA) for Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular Degeneration (CAG-00066R4)

Expand/collapse the Contacts section

Contact(s)

James Rollins, MD

Kimberly Long

kimberly.long@cms.hhs.gov

410-786-5702

Back to Top

Expand/collapse the Documents section

Documents

Tracking Sheet

Proposed Decision Memo

Decision Memo

View Public Comments

NCD for Verteporfin (80.3.1)

Back to Top

Expand/collapse the History of Considerations section

History of Considerations

Original Consideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066N)

First reconsideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R)

Second reconsideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R2)

Third reconsideration for Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (CAG-00066R3)

Fourth reconsideration for Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular Degeneration (this document)

Back to Top

Footer Links

www